Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA reduced its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,630 shares of the medical research company’s stock after selling 415 shares during the period. CHICAGO TRUST Co NA’s holdings in Exact Sciences were worth $597,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Exact Sciences by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after purchasing an additional 7,873 shares during the last quarter. Champlain Investment Partners LLC increased its stake in shares of Exact Sciences by 10.9% in the third quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock worth $169,924,000 after buying an additional 245,980 shares during the last quarter. Bellevue Group AG raised its holdings in Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after acquiring an additional 290,585 shares in the last quarter. Armistice Capital LLC boosted its stake in Exact Sciences by 91.6% during the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock valued at $59,154,000 after acquiring an additional 669,438 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock worth $88,017,000 after acquiring an additional 45,015 shares in the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Robert W. Baird reduced their price target on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Citigroup decreased their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Jefferies Financial Group upped their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Raymond James reaffirmed a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. Finally, Sanford C. Bernstein increased their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.94.

Exact Sciences Trading Up 3.6 %

Shares of EXAS stock opened at $58.51 on Tuesday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The firm has a market capitalization of $10.83 billion, a PE ratio of -50.01 and a beta of 1.24. The stock has a fifty day moving average of $57.57 and a two-hundred day moving average of $58.98. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The company had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. The company’s revenue was up 12.8% on a year-over-year basis. As a group, research analysts expect that Exact Sciences Co. will post -1.13 EPS for the current year.

Insider Buying and Selling

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.36% of the stock is owned by corporate insiders.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.